New Delhi, June 27 -- A new study by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England is set to investigate whether genetic differences influence the risk of developing acute pancreatitis after using GLP-1 receptor agonist drugs - such as Ozempic, Mounjaro, and Wegovy - for weight loss and Type 2 diabetes.

According to Sky News, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has received 181 reports of acute or chronic pancreatitis linked to the weight-loss drug Mounjaro, including five deaths.

The GLP-1 medications Wegovy and Ozempic have been associated with 113 reports of pancreatitis and one death, the outlet reported.

Sky News also noted that other, less commonly used GL...